Insmed to Participate at the UBS Global Healthcare Conference

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on developing orphan treatments for rare pulmonary diseases, today announced that company management will participate at the 2015 UBS Global Healthcare conference taking place at the Sheraton New York Times Square Hotel from May 18 to May 20. Will Lewis, president and chief executive officer of Insmed, will participate in an analyst-led fireside chat on Monday, May 18 at 4:00 PM ET.

Mr. Lewis' presentation will be webcast live and can be accessed by visiting the investor section of the company's website at www.insmed.com. The webcast will be archived for a period of 90 days following the live webcast.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE™, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.